Evidence map›Paper›PMID 29403867›Full record

ArticleJournal of pharmaceutical analysis2014

LC-UV/MS quality analytics of paediatric artemether formulations.

Kirsten Vandercruyssen, Matthias D'Hondt, Valentijn Vergote, Herwig Jansen, Christian Burvenich, Bart De Spiegeleer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. In Vitro and In Vivo Studies of Anti-Lung Cancer Activity ofAntioxidants (Basel, Switzerland) · 2021
    Article
  4. Article
  5. Degradation of Artemisinin-Based Combination Therapies Under Tropical Conditions.The American journal of tropical medicine and hygiene · 2016
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kirsten VandercruyssenDrug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.
Matthias D'HondtDrug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.
Valentijn VergoteDrug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.
Herwig JansenDafra Pharma International, Slachthuisstraat 30/7, B-2300 Turnhout, Belgium.
Christian BurvenichDepartment of Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, B-9820 Merelbeke, Belgium.
Bart De SpiegeleerDrug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A highly selective and stability-indicating HPLC-method, combined with appropriate sample preparation steps, is developed for β-artemether assay and profiling of related impurities, including possible degradants, in a complex powder for oral suspension. Following HPLC conditions allowed the required selectivity: a Prevail organic acid (OA) column (250 mm×4.6 mm, 5 μm), flow rate set at 1.5 mL/min combined with a linear gradient (where

Indexed as

Artemisinin trioxane derivativesMS-fragmentationPaediatric formulationsPolar embedded organic acid columnRelated impurities and degradation compoundsSample preparation

Identifiers

PMID29403867
PMCPMC5761056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.